KR960000231A - 데소게스트렐(desogestrel)을 함유하는 정제, 캡슐, 또는 과립 - Google Patents

데소게스트렐(desogestrel)을 함유하는 정제, 캡슐, 또는 과립 Download PDF

Info

Publication number
KR960000231A
KR960000231A KR1019950014913A KR19950014913A KR960000231A KR 960000231 A KR960000231 A KR 960000231A KR 1019950014913 A KR1019950014913 A KR 1019950014913A KR 19950014913 A KR19950014913 A KR 19950014913A KR 960000231 A KR960000231 A KR 960000231A
Authority
KR
South Korea
Prior art keywords
desogestrel
dissolved
mixed
lubricant
capsules
Prior art date
Application number
KR1019950014913A
Other languages
English (en)
Other versions
KR100380841B1 (ko
Inventor
드 한 피터
게라르두스 요셉 에그버링크 요한네스
Original Assignee
에프. 쥐. 엠. 헤르만스·피. 케이. 브론스
악조 노벨 엔. 브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8216929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR960000231(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 에프. 쥐. 엠. 헤르만스·피. 케이. 브론스, 악조 노벨 엔. 브이. filed Critical 에프. 쥐. 엠. 헤르만스·피. 케이. 브론스
Publication of KR960000231A publication Critical patent/KR960000231A/ko
Application granted granted Critical
Publication of KR100380841B1 publication Critical patent/KR100380841B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 유기 용매가 없는 윤활제, 및 윤활제가 아닌 함납 물질 중에서 선택되는 고형물중에 데소게스트렐이 혼합되거나 용해되어 있는 것을 특징으로 하는 데소게스트렐을 함유하는 경구 투여용 정제, 캡슐, 또는 과립에 관한 것이다.

Description

데소게스트렐(desogestrel)을 함유하는 정제, 캡슐, 또는 과립
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 유기 용매가 없는 윤활제 및 윤활제가 아닌 함납 물질 중에서 선택되는 고형물중에 데소게스트렐이 혼합되거나 용해되어 있는 것을 특징으로 하는 데소게스트렐을 함유하는 경구 투여용 정제, 캡슐, 또는 과립.
  2. 제1항에 있어서, 데소게스트렐이 인지질류, 당지질류, 지단백류, 친수성 또는 친지성 함납물질, 지방족 알콜류, 폴리에틸렌 글리콜류, 소르비탄 지방산의 폴리옥시에틸렌 유도체류, 지방산류 또는 이의 에스테르류 및 이들의 혼합물중에서 선택되는 고형물중에 혼합되거나, 용해되어 있는 정제, 캡슐 또는 과립.
  3. 제2항에 있어서, 데소게스트렐이 고형 지방산 또는 이의 1가 알콜 에스테르 또는 글리세롤에스테르 중에 혼합되거나, 용해되어 있는 정제, 캡슐 또는 과립.
  4. 제1항 내지 제3항중 어느 한 항에 있어서, 고형물중에 혼합되거나, 용해되어 있는 데소게스트렐이 추가로 에스트로겐을 함유하는 정제, 캡슐 또는 과립.
  5. 데소게스트렐이 이동하지 않는 의약 조성물을 수득하기 위해, 유기 용매가 없는 윤활제 및 윤활제가 아닌 함납 물질 중에서 선택되는 고형물중에 혼합되거나 용해되어 있는 데소게스트렐을 함유하는 정제, 캡슐, 또는 과립을 사용하는 방법.
  6. 데소게스트렐 및 임의적으로 에스트로겐을 유기 용매가 없는 고형 윤활제중에 용해 또는 혼합하거나, 윤활제가 아닌 함납 물질 및 임의적으로 유기 용매중에 용해 또는 혼합한 다음, 그 용매 또는 혼합물을 담체 물질 상에 분산시키고, 임의적으로 존재한다면 용매를 증발시킨 후, 산출되는 약물-부하된 담채 물질을 임의적으로 보조제 및/또는 윤활제와 혼합하거나, 또는 함납 물질 중에서 액화 용융된 데소게스트렐 및 임의의 에스트로겐 분산액을 직접 냉각시킨 후 이어서 고형 물질을 소립자 크기로 선별한 다음, 결과적으로 산출되는 약물-부하된 혼합물을 과립화하거나, 정제로 압축하거나, 또는 캡슐내에 충진시키는 것으로 구성되는 것을 특징으로 하는, 고형물내에 데소게스트렐 및 임의 성분인 에스트로겐을 병입시키는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950014913A 1994-06-08 1995-06-07 데소게스트렐(desogestrel)을함유하는정제또는캡슐 KR100380841B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94201625 1994-06-08
EP94201625.4 1994-06-08

Publications (2)

Publication Number Publication Date
KR960000231A true KR960000231A (ko) 1996-01-25
KR100380841B1 KR100380841B1 (ko) 2003-08-14

Family

ID=8216929

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950014913A KR100380841B1 (ko) 1994-06-08 1995-06-07 데소게스트렐(desogestrel)을함유하는정제또는캡슐

Country Status (19)

Country Link
US (1) US5709881A (ko)
EP (1) EP0688565B2 (ko)
JP (1) JP4302783B2 (ko)
KR (1) KR100380841B1 (ko)
CN (1) CN1057673C (ko)
AT (1) ATE254921T1 (ko)
AU (1) AU697512B2 (ko)
BR (1) BR9502704A (ko)
CA (1) CA2150642C (ko)
DE (1) DE69532176T3 (ko)
DK (1) DK0688565T4 (ko)
ES (1) ES2210272T5 (ko)
FI (1) FI952765A (ko)
HK (1) HK1001996A1 (ko)
HU (1) HU218282B (ko)
IL (1) IL113816A (ko)
NZ (1) NZ272285A (ko)
PT (1) PT688565E (ko)
RU (1) RU2160107C2 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5209600A (en) * 1999-04-06 2000-10-23 Akzo Nobel N.V. Orally active androgens
JP4902918B2 (ja) * 1999-07-30 2012-03-21 スミスクライン ビーチャム ピー エル シー 多成分医薬剤形
ES2739023T3 (es) * 2001-07-06 2020-01-28 Veloxis Pharmaceuticals As Aglomeración controlada
TW200403075A (en) * 2002-05-29 2004-03-01 Akzo Nobel Nv Progestagenic dosage units
CN105030792B (zh) * 2015-06-30 2017-08-25 上海交通大学 Desogestrel在制备抗结肠癌/ER阴性的Ah受体阳性的乳腺癌产品中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56140915A (en) † 1980-04-07 1981-11-04 Yamanouchi Pharmaceut Co Ltd Pharmaceutical preparation for solid drug
DE3421468A1 (de) * 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
EP0300523B1 (en) 1987-07-06 1991-08-14 Akzo N.V. Pharmaceutical dosage unit for the prevention or treatment of climacteric complaints
EP0368373A1 (en) * 1988-10-13 1990-05-16 Akzo Nobel N.V. Multi-phase contraceptive preparation
US4948593A (en) * 1989-05-15 1990-08-14 Alza Corporation Osmotic dosage form comprising an estrogen and a progestogen
US5395627A (en) † 1992-09-04 1995-03-07 Akzo N.V. Pharmaceutical granulate

Also Published As

Publication number Publication date
AU2053195A (en) 1995-12-14
HUT71491A (en) 1995-11-28
EP0688565B2 (en) 2007-11-21
FI952765A0 (fi) 1995-06-06
PT688565E (pt) 2004-03-31
JP4302783B2 (ja) 2009-07-29
CA2150642A1 (en) 1995-12-09
DE69532176T2 (de) 2004-08-12
HU218282B (en) 2000-07-28
US5709881A (en) 1998-01-20
ES2210272T5 (es) 2008-05-01
EP0688565B1 (en) 2003-11-26
JPH07330610A (ja) 1995-12-19
DK0688565T3 (da) 2004-03-29
RU2160107C2 (ru) 2000-12-10
DE69532176D1 (de) 2004-01-08
IL113816A (en) 1998-12-06
ES2210272T3 (es) 2004-07-01
DE69532176T3 (de) 2008-06-12
CN1057673C (zh) 2000-10-25
CA2150642C (en) 2008-04-22
BR9502704A (pt) 1996-03-05
ATE254921T1 (de) 2003-12-15
HK1001996A1 (en) 1998-07-24
DK0688565T4 (da) 2008-03-17
EP0688565A1 (en) 1995-12-27
AU697512B2 (en) 1998-10-08
NZ272285A (en) 1996-08-27
HU9501654D0 (en) 1995-07-28
CN1122226A (zh) 1996-05-15
KR100380841B1 (ko) 2003-08-14
FI952765A (fi) 1995-12-09
IL113816A0 (en) 1995-08-31

Similar Documents

Publication Publication Date Title
US4869900A (en) Pharamaceutical composition containing ubidecarenone
RU2207859C1 (ru) Фармацевтические композиции для перорального применения, содержащие длинноцепочечные триглицериды и липофильные поверхностно-активные вещества
CA2106423C (en) Stabilized pharmaceutical compositions containing derivatives of vitamins d2 and d3
NZ749142A (en) Cannabinoid formulations
KR930701983A (ko) 방출억제성 베라파밀 정제
GB938828A (en) Improvements in or relating to pharmaceutical capsules comprising radioactive materials
KR890001521A (ko) 서방형 신규 제약 제제물
ES2164339T3 (es) Composiciones farmaceuticas para administracion oral que contienen hormonas sexuales.
KR870700018A (ko) 클로로플루오로카본 연무질 포사약 조성물을 함유하는 약제
CA2216934A1 (en) Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
KR980000466A (ko) 사이클로스포린-함유 연질캅셀제
AU777740B2 (en) Pharmaceutical compositions for oral and topical administration
CA2137764C (en) Pharmaceutical compositions comprising solutions or dispersions of a staurosporine active ingredient in a saturated polyalkylene glycol glyceride
US3136695A (en) Anhydrous thixotropic gel sustained release therapeutic compositions and method of preparation
KR960000231A (ko) 데소게스트렐(desogestrel)을 함유하는 정제, 캡슐, 또는 과립
DE69820674T2 (de) Poröse hydroxyapatit-partikel als träger für medikamente
CA2532566A1 (en) Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
JP2001031565A (ja) ロキソプロフェンナトリウム含有カプセル製剤
EP0276116A2 (en) Capsule filling
RU95109859A (ru) Таблетка, капсула или гранула, содержащая дезогестрел, ее применение, способ введения дезогестрела и необязательно эстрогена в твердое вещество
US5189066A (en) Pharmaceutical compositions of tebufelone
AU654143B2 (en) Amantadine hydrochloride suspension with enhanced dissolution characteristics for use in soft gelatin capsules
EP0431659B1 (en) Pharmaceutical compositions of tebufelone
TH20324A (th) ยาเม็ด แคปซูล หรือ แกรนูลที่ประกอบด้วยดีโซเจสเทรล
JP4048389B2 (ja) シクロスポリン軟カプセル剤

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20090406

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee